Patents by Inventor Jesse I. Yoo

Jesse I. Yoo has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • FORMULATIONS FOR SUPRACHOROIDAL ADMINISTRATION SUCH AS HIGH VISCOSITY FORMULATIONS
    Publication number: 20240024508
    Abstract: Provided herein are pharmaceutical compositions for administration to a suprachoroidal space of an eye of a subject. The pharmaceutical compositions can include a recombinant adeno-associated virus (AAV) encoding a transgene. Also provided herein are methods for treating or preventing a disease in a subject by administering a therapeutically effective amount of the pharmaceutical compositions to the subject in need.
    Type: Application
    Filed: October 6, 2021
    Publication date: January 25, 2024
    Inventors: Jared Bee, Tristan James Marshall, Sherri Van Everen, Stephen Joseph Pakola, Nicholas Alexander Piers Sascha Buss, Anthony Ray O'Berry, Jesse I. Yoo, Ewa Budzynski
  • FORMULATIONS FOR SUPRACHOROIDAL ADMINISTRATION SUCH AS GEL FORMULATIONS
    Publication number: 20230414788
    Abstract: Provided herein are pharmaceutical compositions for administration to a suprachoroidal space of an eye of a subject. The pharmaceutical compositions can include a recombinant adeno-associated virus (AAV) encoding a transgene. Also provided herein are methods for treating or preventing a disease in a subject by administering a therapeutically effective amount of the pharmaceutical compositions to the subject in need.
    Type: Application
    Filed: October 6, 2021
    Publication date: December 28, 2023
    Inventors: Jared Bee, Tristan James Marshall, Sherri Van Everen, Stephen Joseph Pakola, Nicholas Alexander Piers Sascha Buss, Anthony Ray O'Berry, Jesse I. Yoo, Ewa Budzynski
  • TREATMENT OF DIABETIC RETINOPATHY WITH FULLY-HUMAN POST-TRANSLATIONALLY MODIFIED ANTI-VEGF FAB
    Publication number: 20220280608
    Abstract: Compositions and methods are described for the delivery of a fully human post-translaionally modified (HuPTM) monoclonal antibody (“mAh”) or the antigen-binding fragment of a mAh against human vascular endothelial growth factor (“hVEGF”)—such as, e.g., a fully human-glycosylated (HuGly) anti-hVEGF antigen-binding fragment—to the retina/vitreal humour in the eye(s) of human subjects diagnosed with diabetic retinopathy.
    Type: Application
    Filed: August 25, 2020
    Publication date: September 8, 2022
    Inventors: Stephen Joseph Pakola, Sherri Van Everen, Jesse I. Yoo, Samir Maganbhai Patel, Avanti Arvind Ghanekar, Anthony Ray O'Berry, Kim Rees Irwin-Pack, Darin Thomas Curtiss
  • Gene Therapy For Eye Pathologies
    Publication number: 20220143221
    Abstract: Compositions and methods are described for the delivery of therapeutic products (such as therapeutic proteins (for example, antibodies), therapeutic RNAs (for example, shRNAs, siRNAs, and miRNAs), and therapeutic aptamers) to the retina/vitreal humour in the eyes of human subjects to treat pathologies of the eye, involving, for example, recombinant viral vectors such as recombinant adeno-associated virus (rAAV) vectors.
    Type: Application
    Filed: April 2, 2020
    Publication date: May 12, 2022
    Applicant: REGENXBIO, Inc.
    Inventors: Olivier Danos, Sherri Van Everen, Jesse I. Yoo, Samir Maganbhai Patel, Avanti Arvind Ghanekar, Anthony Ray O'Berry, Kim Rees Irwin-Pack, Darin Thomas Curtiss